Overview: Fructosamine TestIntroduction: The Fructosamine Test measures fructosamine to monitor short-term blood sugar control in diabetes, preventing complications like fatigue. Following 2023 ADA guidelines, it uses an immunoassay for high sensitivity, aiding in metabolic screening. This test is critical for guiding diabetes management and improving outcomes in biochemistry for diabetic patients.
Other Names: Fructosamine Assay, Glycated Serum Protein Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic accuracy.
Historical Milestone: Fructosamine testing began in the 1980s with diabetes research. Immunoassays emerged in the 1990s, improving accuracy for short-term glycemic monitoring.
Purpose: Monitors short-term blood sugar control, guides diabetes management, and prevents complications in patients with fatigue.
Test Parameters: 1. Fructosamine
Pretest Condition: Fasting for 10-12 hours required to stabilize results. Collect serum or plasma in the morning. Report symptoms like fatigue, and list medications.
Specimen: 2-5 mL serum (SST) or 2-4 mL plasma (EDTA). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document fatigue, diabetes history, or glycemic control issues. Include current medications, especially antidiabetics.
Consent: Written consent required, detailing the tests purpose, monitoring implications, and potential need for treatment adjustments.
Procedural Considerations: Uses an immunoassay to measure fructosamine levels. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Non-fasting, hemolysis, or medications can affect results. Liver disease may alter levels.
Clinical Significance: Elevated fructosamine levels suggest poor glycemic control, prompting treatment adjustments. Normal levels indicate good control.
Specialist Consultation: Consult an endocrinologist for result interpretation.
Additional Supporting Tests: HbA1c, glucose levels, or CGM to confirm glycemic control.
Test Limitations: Short-term monitoring may miss long-term trends. Results require clinical correlation.
References: ADA Diabetes Guidelines, 2023; Diabetes Care, Nathan DM, 2022.
